Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy
- 1 June 1990
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 130 (1), 91-100
- https://doi.org/10.1016/0022-1759(90)90303-d
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Tumor acquisition, propagation, and preservation. The culture of human colorectal cancerCancer, 1989
- In vitro activation of lymphocytes from nonsmall cell cancer patients by interleukin 2 and anti-CD3 antibodyClinical Immunology and Immunopathology, 1989
- Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2Cellular Immunology, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- The role of T3 in the activation of human T cellsJournal of Clinical Immunology, 1984
- Identification of the Receptor for Antigen and Major Histocompatibility Complex on Human Inducer T LymphocytesScience, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982